Antibody binding to Tie2 and use thereof
The present invention refers to an antibody against Tie-2 or antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a manufacturing method of the antibody or antigen-binding fragment thereof, and a composition for preventing or treating angiogenic diseases, which comprises the antibody or antigen-binding fragment thereof.
1. An anti-Tie2 antibody or antigen-binding fragment thereof which binds Tie2 Ig3-FNIII (1-3) domain comprising the sequence of SEQ ID NO:2, wherein the antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs:3-5, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs:6-8, respectively;
a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs:13-15, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs:16-18, respectively;
a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs:23-25, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs:26-28, respectively;
a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs:33-35, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs:36-38, respectively; or
a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs:43-45, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NO:46-48, respectively.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:9 and a light chain variable region comprising amino acid sequence of SEQ ID NO:11;
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:19 and a light chain variable region comprising amino acid sequence of SEQ ID NO:21;
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:29 and a light chain variable region comprising amino acid sequence of SEQ ID NO:31;
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:39 and a light chain variable region comprising amino acid sequence of SEQ ID NO:41;
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:49 and a light chain variable region comprising amino acid sequence of SEQ ID NO:51;
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:53 and a light chain variable region comprising amino acid sequence of SEQ ID NO:54;
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:57 and a light chain variable region comprising amino acid sequence of SEQ ID NO:58;
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:61 and a light chain variable region comprising amino acid sequence of SEQ ID NO:62; or
a heavy chain variable region comprising amino acid sequence of SEQ ID NO:65 and a light chain variable region comprising amino acid sequence of SEQ ID NO:66.
3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a heavy chain CDRs comprising amino acid sequences of SEQ ID NOs:23-25 and a light chain variable region comprising a light chain CDRs comprising amino acid sequences of SEQ ID NOs:26-28.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising amino acid sequence of SEQ ID NO:29 and a light chain variable region comprising amino acid sequence of SEQ ID NO:31.
5. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable excipient.
6. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 3 and a pharmaceutically acceptable excipient.